SrasV1, PascalFrancis, Corpus, bibRecord, 000680

Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus

Identifieur interne : 000680 ( PascalFrancis/Corpus ); précédent : 000679; suivant : 000681

Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus

Auteurs : Gerold Hoever ; Lidia Baltina ; Martin Michaelis ; Rimma Kondratenko ; Lia Baltina ; Genrich A. Tolstikov ; Hans W. Doerr ; Jindrich Jr Cinatl

Source :

Journal of medicinal chemistry : (Print) [ 0022-2623 ] ; 2005.

RBID : Pascal:05-0238636

Descripteurs français

Pascal (Inist)
- Relation structure activité, Synthèse chimique, Glycyrrhizique acide, Saponine, Oléanane dérivé, Acide uronique, Glycoside, Triterpène, Terpénoïde, Composé pentacyclique, Enone, Glycosylamine, Glycopeptide, Antiviral, Coronavirus, Syndrome respiratoire aigu sévère, In vitro.

English descriptors

KwdEn :
- Antiviral, Chemical synthesis, Coronavirus, Enone, Glycopeptide, Glycoside, Glycosylamine, Glycyrrhizic acid, In vitro, Oleanane derivatives, Pentacyclic compound, Saponin, Severe acute respiratory syndrome, Structure activity relation, Terpenoid, Triterpene, Uronic acid.

Abstract

Glycyrrhizin (GL) was shown to inhibit SARS-coronavirus (SARS-CoV) replication in vitro. Here the anti-SARS-CoV activity of 15 GL derivatives was tested. The introduction of 2-acetamido-β-D-glucopyranosylamine into the glycoside chain of GL resulted in 10-fold increased anti-SARS-CoV activity compared to GL. Amides of GL and conjugates of GL with two amino acid residues and a free 30-COOH function presented up to 70-fold increased activity against SARS-CoV but also increased cytotoxicity resulting in decreased selectivity index.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0022-2623`
A02	`01`			`@0 JMCMAR`
A03		`1`		`@0 J. med. chem. : (Print)`
A05				`@2 48`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus`
A11	`01`	`1`		`@1 HOEVER (Gerold)`
A11	`02`	`1`		`@1 BALTINA (Lidia)`
A11	`03`	`1`		`@1 MICHAELIS (Martin)`
A11	`04`	`1`		`@1 KONDRATENKO (Rimma)`
A11	`05`	`1`		`@1 BALTINA (Lia)`
A11	`06`	`1`		`@1 TOLSTIKOV (Genrich A.)`
A11	`07`	`1`		`@1 DOERR (Hans W.)`
A11	`08`	`1`		`@1 CINATL (Jindrich JR)`
A14	`01`			`@1 Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40 @2 60596 Frankfurt @3 DEU @Z 1 aut. @Z 3 aut. @Z 7 aut. @Z 8 aut.`
A14	`02`			`@1 Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71 @2 450054, Ufa @3 RUS @Z 2 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut.`
A20				`@1 1256-1259`
A21				`@1 2005`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 9165 @5 354000127045660370`
A44				`@0 0000 @1 © 2005 INIST-CNRS. All rights reserved.`
A45				`@0 29 ref.`
A47	`01`	`1`		`@0 05-0238636`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Journal of medicinal chemistry : (Print)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Glycyrrhizin (GL) was shown to inhibit SARS-coronavirus (SARS-CoV) replication in vitro. Here the anti-SARS-CoV activity of 15 GL derivatives was tested. The introduction of 2-acetamido-β-D-glucopyranosylamine into the glycoside chain of GL resulted in 10-fold increased anti-SARS-CoV activity compared to GL. Amides of GL and conjugates of GL with two amino acid residues and a free 30-COOH function presented up to 70-fold increased activity against SARS-CoV but also increased cytotoxicity resulting in decreased selectivity index.
C02	`01`	`X`		`@0 002B02S05`
C03	`01`	`X`	`FRE`	`@0 Relation structure activité @5 01`
C03	`01`	`X`	`ENG`	`@0 Structure activity relation @5 01`
C03	`01`	`X`	`SPA`	`@0 Relación estructura actividad @5 01`
C03	`02`	`X`	`FRE`	`@0 Synthèse chimique @5 02`
C03	`02`	`X`	`ENG`	`@0 Chemical synthesis @5 02`
C03	`02`	`X`	`SPA`	`@0 Síntesis química @5 02`
C03	`03`	`X`	`FRE`	`@0 Glycyrrhizique acide @2 NK @5 03`
C03	`03`	`X`	`ENG`	`@0 Glycyrrhizic acid @2 NK @5 03`
C03	`03`	`X`	`SPA`	`@0 Glicirrícico ácido @2 NK @5 03`
C03	`04`	`X`	`FRE`	`@0 Saponine @5 05`
C03	`04`	`X`	`ENG`	`@0 Saponin @5 05`
C03	`04`	`X`	`SPA`	`@0 Saponina @5 05`
C03	`05`	`X`	`FRE`	`@0 Oléanane dérivé @2 NK @5 06`
C03	`05`	`X`	`ENG`	`@0 Oleanane derivatives @2 NK @5 06`
C03	`05`	`X`	`SPA`	`@0 Oleanano derivado @2 NK @5 06`
C03	`06`	`X`	`FRE`	`@0 Acide uronique @5 07`
C03	`06`	`X`	`ENG`	`@0 Uronic acid @5 07`
C03	`06`	`X`	`SPA`	`@0 Acido urónico @5 07`
C03	`07`	`X`	`FRE`	`@0 Glycoside @5 08`
C03	`07`	`X`	`ENG`	`@0 Glycoside @5 08`
C03	`07`	`X`	`SPA`	`@0 Glicósido @5 08`
C03	`08`	`X`	`FRE`	`@0 Triterpène @5 09`
C03	`08`	`X`	`ENG`	`@0 Triterpene @5 09`
C03	`08`	`X`	`SPA`	`@0 Triterpeno @5 09`
C03	`09`	`X`	`FRE`	`@0 Terpénoïde @2 FX @5 10`
C03	`09`	`X`	`ENG`	`@0 Terpenoid @2 FX @5 10`
C03	`09`	`X`	`SPA`	`@0 Terpenoide @2 FX @5 10`
C03	`10`	`X`	`FRE`	`@0 Composé pentacyclique @5 12`
C03	`10`	`X`	`ENG`	`@0 Pentacyclic compound @5 12`
C03	`10`	`X`	`SPA`	`@0 Compuesto pentacíclico @5 12`
C03	`11`	`X`	`FRE`	`@0 Enone @5 13`
C03	`11`	`X`	`ENG`	`@0 Enone @5 13`
C03	`11`	`X`	`SPA`	`@0 Enona @5 13`
C03	`12`	`X`	`FRE`	`@0 Glycosylamine @5 14`
C03	`12`	`X`	`ENG`	`@0 Glycosylamine @5 14`
C03	`12`	`X`	`SPA`	`@0 Glicosilamina @5 14`
C03	`13`	`X`	`FRE`	`@0 Glycopeptide @5 15`
C03	`13`	`X`	`ENG`	`@0 Glycopeptide @5 15`
C03	`13`	`X`	`SPA`	`@0 Glicopéptido @5 15`
C03	`14`	`X`	`FRE`	`@0 Antiviral @5 17`
C03	`14`	`X`	`ENG`	`@0 Antiviral @5 17`
C03	`14`	`X`	`SPA`	`@0 Antiviral @5 17`
C03	`15`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 18`
C03	`15`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 18`
C03	`15`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 18`
C03	`16`	`X`	`FRE`	`@0 Syndrome respiratoire aigu sévère @2 NM @5 19`
C03	`16`	`X`	`ENG`	`@0 Severe acute respiratory syndrome @2 NM @5 19`
C03	`16`	`X`	`SPA`	`@0 Síndrome respiratorio agudo severo @2 NM @5 19`
C03	`17`	`X`	`FRE`	`@0 In vitro @5 20`
C03	`17`	`X`	`ENG`	`@0 In vitro @5 20`
C03	`17`	`X`	`SPA`	`@0 In vitro @5 20`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Virose`
C07	`04`	`X`	`ENG`	`@0 Viral disease`
C07	`04`	`X`	`SPA`	`@0 Virosis`
C07	`05`	`X`	`FRE`	`@0 Infection`
C07	`05`	`X`	`ENG`	`@0 Infection`
C07	`05`	`X`	`SPA`	`@0 Infección`
N21				`@1 164`
N44	`01`			`@1 PSI`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 05-0238636 INIST
ET :	Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus
AU :	HOEVER (Gerold); BALTINA (Lidia); MICHAELIS (Martin); KONDRATENKO (Rimma); BALTINA (Lia); TOLSTIKOV (Genrich A.); DOERR (Hans W.); CINATL (Jindrich JR)
AF :	Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40/60596 Frankfurt/Allemagne (1 aut., 3 aut., 7 aut., 8 aut.); Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71/450054, Ufa/Russie (2 aut., 4 aut., 5 aut., 6 aut.)
DT :	Publication en série; Niveau analytique
SO :	Journal of medicinal chemistry : (Print); ISSN 0022-2623; Coden JMCMAR; Etats-Unis; Da. 2005; Vol. 48; No. 4; Pp. 1256-1259; Bibl. 29 ref.
LA :	Anglais
EA :	Glycyrrhizin (GL) was shown to inhibit SARS-coronavirus (SARS-CoV) replication in vitro. Here the anti-SARS-CoV activity of 15 GL derivatives was tested. The introduction of 2-acetamido-β-D-glucopyranosylamine into the glycoside chain of GL resulted in 10-fold increased anti-SARS-CoV activity compared to GL. Amides of GL and conjugates of GL with two amino acid residues and a free 30-COOH function presented up to 70-fold increased activity against SARS-CoV but also increased cytotoxicity resulting in decreased selectivity index.
CC :	002B02S05
FD :	Relation structure activité; Synthèse chimique; Glycyrrhizique acide; Saponine; Oléanane dérivé; Acide uronique; Glycoside; Triterpène; Terpénoïde; Composé pentacyclique; Enone; Glycosylamine; Glycopeptide; Antiviral; Coronavirus; Syndrome respiratoire aigu sévère; In vitro
FG :	Coronaviridae; Nidovirales; Virus; Virose; Infection
ED :	Structure activity relation; Chemical synthesis; Glycyrrhizic acid; Saponin; Oleanane derivatives; Uronic acid; Glycoside; Triterpene; Terpenoid; Pentacyclic compound; Enone; Glycosylamine; Glycopeptide; Antiviral; Coronavirus; Severe acute respiratory syndrome; In vitro
EG :	Coronaviridae; Nidovirales; Virus; Viral disease; Infection
SD :	Relación estructura actividad; Síntesis química; Glicirrícico ácido; Saponina; Oleanano derivado; Acido urónico; Glicósido; Triterpeno; Terpenoide; Compuesto pentacíclico; Enona; Glicosilamina; Glicopéptido; Antiviral; Coronavirus; Síndrome respiratorio agudo severo; In vitro
LO :	INIST-9165.354000127045660370
ID :	05-0238636

Links to Exploration step

Pascal:05-0238636

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus</title>
<author><name sortKey="Hoever, Gerold" sort="Hoever, Gerold" uniqKey="Hoever G" first="Gerold" last="Hoever">Gerold Hoever</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40</s1>
<s2>60596 Frankfurt</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baltina, Lidia" sort="Baltina, Lidia" uniqKey="Baltina L" first="Lidia" last="Baltina">Lidia Baltina</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71</s1>
<s2>450054, Ufa</s2>
<s3>RUS</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Michaelis, Martin" sort="Michaelis, Martin" uniqKey="Michaelis M" first="Martin" last="Michaelis">Martin Michaelis</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40</s1>
<s2>60596 Frankfurt</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kondratenko, Rimma" sort="Kondratenko, Rimma" uniqKey="Kondratenko R" first="Rimma" last="Kondratenko">Rimma Kondratenko</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71</s1>
<s2>450054, Ufa</s2>
<s3>RUS</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baltina, Lia" sort="Baltina, Lia" uniqKey="Baltina L" first="Lia" last="Baltina">Lia Baltina</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71</s1>
<s2>450054, Ufa</s2>
<s3>RUS</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tolstikov, Genrich A" sort="Tolstikov, Genrich A" uniqKey="Tolstikov G" first="Genrich A." last="Tolstikov">Genrich A. Tolstikov</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71</s1>
<s2>450054, Ufa</s2>
<s3>RUS</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W." last="Doerr">Hans W. Doerr</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40</s1>
<s2>60596 Frankfurt</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cinatl, Jindrich Jr" sort="Cinatl, Jindrich Jr" uniqKey="Cinatl J" first="Jindrich Jr" last="Cinatl">Jindrich Jr Cinatl</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40</s1>
<s2>60596 Frankfurt</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0238636</idno>
<date when="2005">2005</date>
<idno type="stanalyst">PASCAL 05-0238636 INIST</idno>
<idno type="RBID">Pascal:05-0238636</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000680</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus</title>
<author><name sortKey="Hoever, Gerold" sort="Hoever, Gerold" uniqKey="Hoever G" first="Gerold" last="Hoever">Gerold Hoever</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40</s1>
<s2>60596 Frankfurt</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baltina, Lidia" sort="Baltina, Lidia" uniqKey="Baltina L" first="Lidia" last="Baltina">Lidia Baltina</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71</s1>
<s2>450054, Ufa</s2>
<s3>RUS</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Michaelis, Martin" sort="Michaelis, Martin" uniqKey="Michaelis M" first="Martin" last="Michaelis">Martin Michaelis</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40</s1>
<s2>60596 Frankfurt</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kondratenko, Rimma" sort="Kondratenko, Rimma" uniqKey="Kondratenko R" first="Rimma" last="Kondratenko">Rimma Kondratenko</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71</s1>
<s2>450054, Ufa</s2>
<s3>RUS</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Baltina, Lia" sort="Baltina, Lia" uniqKey="Baltina L" first="Lia" last="Baltina">Lia Baltina</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71</s1>
<s2>450054, Ufa</s2>
<s3>RUS</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tolstikov, Genrich A" sort="Tolstikov, Genrich A" uniqKey="Tolstikov G" first="Genrich A." last="Tolstikov">Genrich A. Tolstikov</name>
<affiliation><inist:fA14 i1="02"><s1>Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71</s1>
<s2>450054, Ufa</s2>
<s3>RUS</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Doerr, Hans W" sort="Doerr, Hans W" uniqKey="Doerr H" first="Hans W." last="Doerr">Hans W. Doerr</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40</s1>
<s2>60596 Frankfurt</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Cinatl, Jindrich Jr" sort="Cinatl, Jindrich Jr" uniqKey="Cinatl J" first="Jindrich Jr" last="Cinatl">Jindrich Jr Cinatl</name>
<affiliation><inist:fA14 i1="01"><s1>Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40</s1>
<s2>60596 Frankfurt</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of medicinal chemistry : (Print)</title>
<title level="j" type="abbreviated">J. med. chem. : (Print)</title>
<idno type="ISSN">0022-2623</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of medicinal chemistry : (Print)</title>
<title level="j" type="abbreviated">J. med. chem. : (Print)</title>
<idno type="ISSN">0022-2623</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Chemical synthesis</term>
<term>Coronavirus</term>
<term>Enone</term>
<term>Glycopeptide</term>
<term>Glycoside</term>
<term>Glycosylamine</term>
<term>Glycyrrhizic acid</term>
<term>In vitro</term>
<term>Oleanane derivatives</term>
<term>Pentacyclic compound</term>
<term>Saponin</term>
<term>Severe acute respiratory syndrome</term>
<term>Structure activity relation</term>
<term>Terpenoid</term>
<term>Triterpene</term>
<term>Uronic acid</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Relation structure activité</term>
<term>Synthèse chimique</term>
<term>Glycyrrhizique acide</term>
<term>Saponine</term>
<term>Oléanane dérivé</term>
<term>Acide uronique</term>
<term>Glycoside</term>
<term>Triterpène</term>
<term>Terpénoïde</term>
<term>Composé pentacyclique</term>
<term>Enone</term>
<term>Glycosylamine</term>
<term>Glycopeptide</term>
<term>Antiviral</term>
<term>Coronavirus</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>In vitro</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Glycyrrhizin (GL) was shown to inhibit SARS-coronavirus (SARS-CoV) replication in vitro. Here the anti-SARS-CoV activity of 15 GL derivatives was tested. The introduction of 2-acetamido-β-D-glucopyranosylamine into the glycoside chain of GL resulted in 10-fold increased anti-SARS-CoV activity compared to GL. Amides of GL and conjugates of GL with two amino acid residues and a free 30-COOH function presented up to 70-fold increased activity against SARS-CoV but also increased cytotoxicity resulting in decreased selectivity index.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-2623</s0>
</fA01>
<fA02 i1="01"><s0>JMCMAR</s0>
</fA02>
<fA03 i2="1"><s0>J. med. chem. : (Print)</s0>
</fA03>
<fA05><s2>48</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>HOEVER (Gerold)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BALTINA (Lidia)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MICHAELIS (Martin)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>KONDRATENKO (Rimma)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BALTINA (Lia)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>TOLSTIKOV (Genrich A.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>DOERR (Hans W.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>CINATL (Jindrich JR)</s1>
</fA11>
<fA14 i1="01"><s1>Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40</s1>
<s2>60596 Frankfurt</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71</s1>
<s2>450054, Ufa</s2>
<s3>RUS</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA20><s1>1256-1259</s1>
</fA20>
<fA21><s1>2005</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>9165</s2>
<s5>354000127045660370</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2005 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>29 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>05-0238636</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of medicinal chemistry : (Print)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Glycyrrhizin (GL) was shown to inhibit SARS-coronavirus (SARS-CoV) replication in vitro. Here the anti-SARS-CoV activity of 15 GL derivatives was tested. The introduction of 2-acetamido-β-D-glucopyranosylamine into the glycoside chain of GL resulted in 10-fold increased anti-SARS-CoV activity compared to GL. Amides of GL and conjugates of GL with two amino acid residues and a free 30-COOH function presented up to 70-fold increased activity against SARS-CoV but also increased cytotoxicity resulting in decreased selectivity index.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Relation structure activité</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Structure activity relation</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Relación estructura actividad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Synthèse chimique</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Chemical synthesis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Síntesis química</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Glycyrrhizique acide</s0>
<s2>NK</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Glycyrrhizic acid</s0>
<s2>NK</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Glicirrícico ácido</s0>
<s2>NK</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Saponine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Saponin</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Saponina</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Oléanane dérivé</s0>
<s2>NK</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Oleanane derivatives</s0>
<s2>NK</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Oleanano derivado</s0>
<s2>NK</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Acide uronique</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Uronic acid</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Acido urónico</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Glycoside</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Glycoside</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Glicósido</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Triterpène</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Triterpene</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Triterpeno</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Terpénoïde</s0>
<s2>FX</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Terpenoid</s0>
<s2>FX</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Terpenoide</s0>
<s2>FX</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Composé pentacyclique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Pentacyclic compound</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Compuesto pentacíclico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Enone</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Enone</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Enona</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Glycosylamine</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Glycosylamine</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Glicosilamina</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Glycopeptide</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Glycopeptide</s0>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Glicopéptido</s0>
<s5>15</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>18</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0>
<s2>NM</s2>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0>
<s2>NM</s2>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0>
<s2>NM</s2>
<s5>19</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>In vitro</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>In vitro</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>In vitro</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>164</s1>
</fN21>
<fN44 i1="01"><s1>PSI</s1>
</fN44>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 05-0238636 INIST</NO>
<ET>Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus</ET>
<AU>HOEVER (Gerold); BALTINA (Lidia); MICHAELIS (Martin); KONDRATENKO (Rimma); BALTINA (Lia); TOLSTIKOV (Genrich A.); DOERR (Hans W.); CINATL (Jindrich JR)</AU>
<AF>Institute of Medical Virology, Johann Wolfgang Goethe University Frankfurt, Paul-Ehrlich-Strasse 40/60596 Frankfurt/Allemagne (1 aut., 3 aut., 7 aut., 8 aut.); Institute of Organic Chemistry, Ufa Research Centre of Russian Academy of Sciences, Prospect Oktyabrya, 71/450054, Ufa/Russie (2 aut., 4 aut., 5 aut., 6 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Journal of medicinal chemistry : (Print); ISSN 0022-2623; Coden JMCMAR; Etats-Unis; Da. 2005; Vol. 48; No. 4; Pp. 1256-1259; Bibl. 29 ref.</SO>
<LA>Anglais</LA>
<EA>Glycyrrhizin (GL) was shown to inhibit SARS-coronavirus (SARS-CoV) replication in vitro. Here the anti-SARS-CoV activity of 15 GL derivatives was tested. The introduction of 2-acetamido-β-D-glucopyranosylamine into the glycoside chain of GL resulted in 10-fold increased anti-SARS-CoV activity compared to GL. Amides of GL and conjugates of GL with two amino acid residues and a free 30-COOH function presented up to 70-fold increased activity against SARS-CoV but also increased cytotoxicity resulting in decreased selectivity index.</EA>
<CC>002B02S05</CC>
<FD>Relation structure activité; Synthèse chimique; Glycyrrhizique acide; Saponine; Oléanane dérivé; Acide uronique; Glycoside; Triterpène; Terpénoïde; Composé pentacyclique; Enone; Glycosylamine; Glycopeptide; Antiviral; Coronavirus; Syndrome respiratoire aigu sévère; In vitro</FD>
<FG>Coronaviridae; Nidovirales; Virus; Virose; Infection</FG>
<ED>Structure activity relation; Chemical synthesis; Glycyrrhizic acid; Saponin; Oleanane derivatives; Uronic acid; Glycoside; Triterpene; Terpenoid; Pentacyclic compound; Enone; Glycosylamine; Glycopeptide; Antiviral; Coronavirus; Severe acute respiratory syndrome; In vitro</ED>
<EG>Coronaviridae; Nidovirales; Virus; Viral disease; Infection</EG>
<SD>Relación estructura actividad; Síntesis química; Glicirrícico ácido; Saponina; Oleanano derivado; Acido urónico; Glicósido; Triterpeno; Terpenoide; Compuesto pentacíclico; Enona; Glicosilamina; Glicopéptido; Antiviral; Coronavirus; Síndrome respiratorio agudo severo; In vitro</SD>
<LO>INIST-9165.354000127045660370</LO>
<ID>05-0238636</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000680 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000680 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:05-0238636
   |texte=   Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus

Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri